Related Experiment Video
Updated: May 9, 2026
09:06
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
MicroRNA-21 in Cancer and Fibrosis: Molecular Mechanisms and Therapeutic Progress
Anushka Sharma1, Awaneet Kaur1, Javed Khan1
1Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Anti-Cancer Agents in Medicinal Chemistry
|May 8, 2026
Summary
MicroRNA-21 (miR-21) drives cancer and fibrosis by affecting cell growth and matrix remodeling. While miR-21 is a promising biomarker and therapeutic target, challenges in delivery and off-target effects impede clinical translation.
Area of Science:
- Molecular Biology
- Oncology
- Fibrosis Research
Background:
- MicroRNA-21 (miR-21) is a critical regulator of gene expression implicated in cancer progression and fibrotic diseases.
- Dysregulated miR-21 promotes tumor growth, metastasis, and fibrosis by inhibiting tumor suppressors and activating pro-fibrotic pathways like TGF-β signaling.
- Its consistent alteration makes miR-21 a potential biomarker for diagnosis, prognosis, and treatment monitoring in various conditions.
Purpose of the Study:
- To review the current literature on microRNA-21 (miR-21) biogenesis, regulation, and functional roles.
- To evaluate therapeutic strategies targeting miR-21 in cancers and fibrotic disorders.
- To identify challenges and future directions for clinical application of miR-21 inhibition.
Main Methods:
- Comprehensive literature review of studies on miR-21 in cancer and fibrosis.
- Analysis of preclinical therapeutic strategies including antagomiRs, LNAs, CRISPR-based inhibition, and delivery systems.
- Evaluation of challenges and limitations in clinical translation of miR-21 targeted therapies.
Main Results:
- miR-21 is a key driver of cancer and fibrosis, influencing cell proliferation, apoptosis resistance, EMT, and ECM remodeling.
- Preclinical studies show promise for various miR-21 inhibition strategies (antagomiRs, LNAs, CRISPR, nanoparticles, viral vectors).
- Significant hurdles remain, including off-target effects, inefficient delivery, and context-dependent miR-21 function, limiting clinical translation.
Conclusions:
- MicroRNA-21 (miR-21) is a pivotal factor in cancer and fibrosis, presenting substantial potential as both a biomarker and therapeutic target.
- Current therapeutic approaches show promise but face challenges in safety and efficacy for clinical application.
- Future research must prioritize precision-based strategies, advanced gene-editing technologies, and improved preclinical models to advance miR-21 targeted therapies.
Related Concept Videos
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...